Read More

NeuroBo Pharma Reports Recommendation From Independent Safety Data Monitoring Committee Of Phase 2/3 Trial Of ANA001 In Hospitalized Patients With Severe COVID-19: Committee Advises Continuation Of Trial Without Modification

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases,

NRBO